2023.07.31
Professor Song Guangyuan and His Team at···
On July 26, 2023, Professor Song Guangyuan, the Director of the Heart Valve Intervention Center at B···
2023.07.07
NMPA APPROVAL FOR REGISTRATION APPLICATI···
This announcement is made by Peijia Medical Limited (the “Company”, together with its
subsidiaries,···
2023.05.18
First Asian Commercial Implants with the···
On May 12th, 2023, Dr. Michael Lee and his team from the Cardiology Department of Queen Elizabeth Ho···
2022.12.04
FIRST PATIENT ENROLLMENT IN THE MULTI-CE···
FIRST PATIENT ENROLLMENT IN THE MULTI-CENTER
REGISTRATION CLINICAL TRIAL OF GeminiOne®
TRANSCATHET···
2022.11.25
FIRST PATIENT IMPLANT IN THE FIRST-IN-MA···
FIRST PATIENT IMPLANT IN THE FIRST-IN-MAN CLINICAL
TRIAL OF THE MonarQ TRANSCATHETER TRICUSPID VALV···
2022.11.14
FIRST PATIENT IMPLANT IN MULTI-CENTER RE···
FIRST PATIENT IMPLANT IN MULTI-CENTER REGISTRATION
CLINICAL TRIAL OF PEIJIA HighLife® TRANSCATHETER···
2022.06.09
Peijia Medical Fluxcap® Balloon Guide Ca···
On June 8, 2022, Peijia Medical received the approval from the National Medical Products Administrat···
2022.05.24
Peijia Medical Tethys AS® Aspiration Cat···
Peijia Medical Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Dilation Catheter Obta···
2022.02.17
NMPA Approval for Registration Applicati···
On February 11, 2022, Peijia Medical Limited (the “Company”) received the approval from the National···
2022.01.08
The First Clinical Case using HighLife T···
On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement (“···
2021.11.01
Peijia Medical Announces First Patient T···
A major breakthrough in interventional therapy for heart valve disease and an innovative progress in···
2021.09.14
Peijia Medical Announces First Patient I···
Peijia Medical today announced the initiation of its multi-center clinical trial for TaurusNXT®, the···